|Bid||35.13 x 900|
|Ask||35.12 x 1200|
|Day's Range||34.35 - 35.52|
|52 Week Range||27.91 - 41.00|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||29.50|
|Earnings Date||Apr 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.35|
NEW YORK, April 19, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. On this news, Boston Scientific's stock price fell $2.90 per share, or 7.67%, over the following two trading sessions, closing at $34.91 on April 17, 2019.
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products. The FDA on Tuesday ordered Boston Scientific and Danish firm Coloplast A/S to immediately pull their mesh implants from the market as the companies did not demonstrate a reasonable assurance of safety and effectiveness of the devices. The company said it will continue to assess any potential additional impact to the business due to the FDA's decision that applies to two of Boston Scientific's products.
Boston Scientific toppled Tuesday after the Food and Drug Administration ordered it and a Danish company to stop selling a medical device that repairs pelvic organ prolapse in women.
Even for the brightest among us, our current healthcare system is a convoluted mess that's difficult to fully understand. With terms like HMOs, PPOs and PFPMs, searching for the right coverage is often as desirable as doing your taxes. However, a political movement to simplify the system has serious implications for you and your portfolio (via healthcare stocks).Earlier this week, Senator Bernie Sanders explained his ambitious plan for a single-payer healthcare system. Broadly, what this entails is that all Americans will enjoy comprehensive health coverage. Under his "Medicare for All Act," patients won't have to pay out of pocket for doctor visitations. It has raised eyebrows because the proposal is considerably more generous than other single-payer countries.Even more startling for both supporters and opponents, Sanders' plan has generated significant support. In particular, presidential candidates Elizabeth Warren, Cory Booker, Kamala Harris and Kirsten Gillibrand cosponsored the bill. With momentum rising, so too has the importance for healthcare stocks to watch.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOne of the striking components of Sanders' plan is its scope. If it passes, all invoices will eventually go to the federal government. Theoretically, this approach does away with some of the volatile pricing imposed within the current system. But such pricing changes would severely impact healthcare stocks.Another sticking point regarding this comprehensive proposal is a possible existential crisis. In many ways, healthcare stocks exist because our broader medical umbrella is so convoluted. Plus, pharmaceuticals can radically hike drug prices, knowing that insurers and patients have little recourse. * 7 Stocks to Buy for Spring Season Growth Of course, paying for a new system would require a substantial tax influx. Sanders hasn't provided a convincing financial plan to accommodate his bill. Nevertheless, the current political environment suggests a change is coming. Here are five healthcare stocks to watch, just in case. UnitedHealth Group (UNH)Source: Shutterstock On Thursday, shares of UnitedHealth Group (NYSE:UNH) tumbled over 4%, and I can't say that I'm surprised. Sure, the commonly cited explanation for why UNH stock took a hit was an analyst downgrade. But the reality is that among healthcare stocks to watch, insurance providers suffer the most risk.Naturally, the Medicare for All Act weighs heavily on UNH stock. Insurers thrive on both the complexity of our healthcare system and the necessity for it. Going without insurance just isn't smart, considering the likelihood of a catastrophic event or disease. According to a shocking BBC report last year, cancer is rising everywhere, including in developed nations.Moreover, fighting that awful disease isn't cheap, with average treatments running well into six digits. The threat of financial ruin is enough for people to run to insurance companies. But with government-endorsed mandated coverage, it's unclear how for-profit insurers like UNH stock can thrive. Cigna (CI)Source: Shutterstock Also on Thursday, shares of Cigna (NYSE:CI) fell sharply, losing 2.5%. Again, I'm not surprised. Compared to other healthcare stocks to watch, CI stock faces an existential threat. If the Medicare for All Act passes, it has severe implications for the insurance company.As we discussed, Sanders' plan is incredibly comprehensive. In his vision of a covered America, no one reaches into their wallets. Whether you're seeing a doctor, getting your teeth cleaned at the dentist's office, or trying on a new pair of eyeglasses, sticker shock in this arena will be obsolete. * 10 S&P 500 Stocks to Weather the Earnings Storm Of course, the problem is that CI stock thrives on this sticker shock. When you cut through all the corporate BS, you realize that the insurance industry prospers on fear. But a government-mandated coverage plan eliminates that fear with a safety net. Thus, I'm currently hesitant on Cigna, and other insurance-related healthcare stocks. Pfizer (PFE)Source: Kojach Via FlickrAlthough insurance companies present an easy target in light of recent political developments, pharmaceuticals can't dodge the bullet, either. Investors and especially current shareholders of Pfizer (NYSE:PFE) should adopt a very cautious stance. On Thursday, PFE stock dipped more than 1%.As with the first two healthcare stocks to watch, Pfizer's pensive trading isn't surprising. In prior generations, a rising tide lifted all boats. But in the next few years, a receding tide could strand everyone. That might be the case for PFE stock, and similar rivals in the pharmaceutical space.As the controversy surrounding the "pharma bro" incident revealed, pharmaceuticals can get away with charging ridiculous prices. But with the Medicare for All Act, that type of predatory behavior -- or even robust capitalism -- stops. When you have to answer to the federal government, suddenly, everyone plays nice.That's great for patients, but not so much for PFE stock. Boston Scientific (BSX)Source: Boston Scientific Ordinally, I wouldn't issue a cautionary note on Boston Scientific (NYSE:BSX). As one of the world's premiere medical-equipment providers, BSX stock represents a life-saving investment. Plus, shares have generally performed well following the aftermath of the Great Recession.Unfortunately, that might change in the coming years, especially if the Medicare for All Act passes. Similar to the plight of other medical stocks to watch, Boston Scientific absorbed a noticeable 1% decline on Thursday. That's just the beginning if the worst-case scenario occurs. * 10 Dividend Growth Stocks You Can't Miss Primarily, BSX stock will essentially lose out on a free market. Instead, a government-imposed network will dictate product pricing and other core details. Essentially, this eliminates the profit motive for Boston Scientific. Since many developed countries have some sort of single-payer system, BSX must cope with the loss of a viable partner. HCA Healthcare (HCA)Source: Shutterstock On surface level, HCA Healthcare (NYSE:HCA) should be one of the healthcare stocks to watch…for a positive reason. Following the end of the Obama administration, Gallup reported a conspicuous rise in the number of uninsured Americans. But under Medicare for All, the insured will likely represent a surge in demand for HCA stock.That's a strong benefit, but it's probably not a net benefit. I say this because the markets really punished HCA stock on Thursday, dropping it down nearly 3%. The most common explanation is that the rest of the sector was also volatile. If other segments within the healthcare industry falls, so too will HCA.But the overriding factor behind the single-payer proposal is big government. So even if the uninsured flock to hospitals and clinics, they can't adopt capitalistic pricing. Instead, the feds will oversee everything, ensuring everyone has access to equal and "fair" healthcare.It's a great deal for patients, but not so much for hospitals, or anyone in this industry for that matter.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * FAANNG Stocks, Ranked From Cheapest to Most Expensive * 7 Stocks With a Lot on the Line This Earnings Season * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Compare Brokers The post 5 Healthcare Stocks to Watch If America Chooses a Single-Payer System appeared first on InvestorPlace.
The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop their sale and distribution in the United States, the latest action by the agency to tackle safety issues related to the devices. The FDA said Boston Scientific Corp and Coloplast A/S did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket applications. The companies will have 10 days to submit their plan to withdraw these products from the market, the FDA said in a statement https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm636114.htm.
Although the surgical meshes represent only about 0.2 percent of Coloplast’s total revenue, the FDA removal of the products suggest the more than 48,000 surgical mesh patients suing Boston Scientific could have a strong case. The surgical meshes were the topic of a “60 Minutes” investigation in 2018.
After more than a decade of complaints and lawsuits, the FDA has ordered Boston Scientific and another company that makes vaginal mesh implants to stop selling the products.
The Food and Drug Administration orders Boston Scientific and Coloplast to stop selling surgical mesh used for some pelvic operations.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares...
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
MARLBOROUGH, Mass. , March 27, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
The positive result regarding Boston Scientific's (BSX) LUMINIZE RF Balloon Catheter is expected to help the company further advance with the procedures to clinch a CE Mark for the instrument.
All three major indexes closed in positive territory, despite reports that a meeting between President Donald Trump and Chinese President Xi Jinping may not happen until June. Investors are feeling relatively upbeat as they await news from global central banks this week, including the Federal Reserve on Wednesday. The Dow Jones Industrial Average rose 65.23 points, or 0.3%, to 25,914.1, while the S&P 500 ticked up 10.46 points, or 0.4%, to 2,832.94 and the Nasdaq Composite added 25.95 points, or 0.3%, to 7,714.48.
The news around paclitaxel is clearly negative and likely to meaningfully limit Eluvia sales, the analyst said. The FDA said Friday that it notified doctors that stents coated with the common cancer chemotherapy drug paclitaxel may be associated with a higher incidence of death in patients.
LISBON, Portugal and MARLBOROUGH, Mass., March 17, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA 2019, the annual congress of the European Heart Rhythm Association in Lisbon, Portugal. Patients with arrhythmias such as AF are often treated with anti-arrhythmic drugs as well as cardiac ablation.
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.